Literature DB >> 1393899

Revised guidelines for booster vaccination against hepatitis B.

D Holton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1393899      PMCID： PMC1336291     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Persistence of anti-HBs and protective efficacy after administration of hepatitis B vaccine.

Authors:  K Yoshida; S Fujiyama; T Sato
Journal:  J Gastroenterol Hepatol       Date:  1990 Mar-Apr       Impact factor: 4.029

2.  Persistence of specific antibodies after hepatitis B vaccination.

Authors:  W Jilg; M Schmidt; F Deinhardt
Journal:  J Hepatol       Date:  1988-04       Impact factor: 25.083

3.  Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population.

Authors:  R B Wainwright; B J McMahon; L R Bulkow; D B Hall; M A Fitzgerald; A P Harpster; S C Hadler; A P Lanier; W L Heyward
Journal:  JAMA       Date:  1989-04-28       Impact factor: 56.272

4.  Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.

Authors:  S C Hadler; D P Francis; J E Maynard; S E Thompson; F N Judson; D F Echenberg; D G Ostrow; P M O'Malley; K A Penley; N L Altman
Journal:  N Engl J Med       Date:  1986-07-24       Impact factor: 91.245

5.  Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results.

Authors:  R B Wainwright; B J McMahon; L R Bulkow; A J Parkinson; A P Harpster
Journal:  Arch Intern Med       Date:  1991-08
  5 in total
  1 in total

1.  Response to a booster dose 18 months after a low anti-HBs response (10-99 IU/l) to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine.

Authors:  J Struve; B Aronsson; B Frenning; M Forsgren; O Weiland
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.